These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 19878123)
41. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. Reardon G; Schwartz GF; Kotak S BMC Ophthalmol; 2010 Mar; 10():5. PubMed ID: 20196848 [TBL] [Abstract][Full Text] [Related]
42. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301 [TBL] [Abstract][Full Text] [Related]
44. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. Schwartz GF; Tan J; Kotak S J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264 [TBL] [Abstract][Full Text] [Related]
45. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Stewart WC; Konstas AG; Nelson LA; Kruft B Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886 [TBL] [Abstract][Full Text] [Related]
46. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. Miki T; Naito T; Fujiwara M; Araki R; Kiyoi R; Shiode Y; Fujiwara A; Morizane Y; Shiraga F PLoS One; 2017; 12(7):e0181550. PubMed ID: 28727804 [TBL] [Abstract][Full Text] [Related]
47. Effect of acute increases of intraocular pressure on corneal pachymetry in eyes treated with travoprost: an animal study. Bolívar G; Teus M; Arranz-Marquez E Curr Eye Res; 2011 Nov; 36(11):1014-9. PubMed ID: 21942300 [TBL] [Abstract][Full Text] [Related]
48. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits. Giannico AT; Lima L; Russ HH; Montiani-Ferreira F J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234 [TBL] [Abstract][Full Text] [Related]
50. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results. Lee H; Cho BJ J Ocul Pharmacol Ther; 2015 Apr; 31(3):152-5. PubMed ID: 25621500 [TBL] [Abstract][Full Text] [Related]
51. Efficiency of instillation methods for prostaglandin medications. Fiscella R; Wilensky JT; Chiang TH; Walt JG J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816 [TBL] [Abstract][Full Text] [Related]
52. Effect of ketorolac add-on treatment on intra-ocular pressure in glaucoma patients receiving prostaglandin analogues. Turan-Vural E; Torun-Acar B; Acar S Ophthalmologica; 2012; 227(4):205-9. PubMed ID: 22116588 [TBL] [Abstract][Full Text] [Related]
53. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study. Macky TA J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177 [TBL] [Abstract][Full Text] [Related]
54. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. Aptel F; Cucherat M; Denis P J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464 [TBL] [Abstract][Full Text] [Related]
56. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. Hariharan S; Minocha M; Mishra GP; Pal D; Krishna R; Mitra AK J Ocul Pharmacol Ther; 2009 Dec; 25(6):487-98. PubMed ID: 20028257 [TBL] [Abstract][Full Text] [Related]
57. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191 [TBL] [Abstract][Full Text] [Related]
58. New topical drugs for open-angle glaucoma. Drug Ther Bull; 2003 Feb; 41(2):12-4. PubMed ID: 12630335 [TBL] [Abstract][Full Text] [Related]
59. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Gagliuso DJ; Wang RF; Mittag TW; Podos SM Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714 [TBL] [Abstract][Full Text] [Related]
60. Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues. Kocabeyoglu S; Mocan MC; Irkec M Indian J Ophthalmol; 2015 Jan; 63(1):15-9. PubMed ID: 25686056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]